Sangamo Therapeutics, Inc.

DB:GBY Stock Report

Market Cap: €426.6m

Sangamo Therapeutics Valuation

Is GBY undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of GBY when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: GBY (€2.28) is trading below our estimate of fair value (€122.83)

Significantly Below Fair Value: GBY is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for GBY?

Key metric: As GBY is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for GBY. This is calculated by dividing GBY's market cap by their current revenue.
What is GBY's PS Ratio?
PS Ratio8.6x
SalesUS$52.29m
Market CapUS$448.53m

Price to Sales Ratio vs Peers

How does GBY's PS Ratio compare to its peers?

The above table shows the PS ratio for GBY vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average9.4x
FYB Formycon
13.5x32.5%€818.4m
BIO3 Biotest
1.4x-4.1%€1.4b
MOR MorphoSys
10.2xn/a€2.6b
HPHA Heidelberg Pharma
12.5x16.6%€106.3m
GBY Sangamo Therapeutics
8.6x41.8%€448.5m

Price-To-Sales vs Peers: GBY is good value based on its Price-To-Sales Ratio (8.6x) compared to the peer average (9.5x).

Price to Sales Ratio vs Industry

How does GBY's PS Ratio compare vs other companies in the DE Biotechs Industry?

7 CompaniesPrice / SalesEstimated GrowthMarket Cap
BIO3 Biotest
1.4x-4.1%US$1.44b
CNW co.don
0.7xn/aUS$6.97m
V9Z Aceragen
0.4xn/aUS$3.12m
PA8 Paion
0.2x30.2%US$2.78m
GBY 8.6xIndustry Avg. 7.9xNo. of Companies7PS0612182430+
7 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: GBY is expensive based on its Price-To-Sales Ratio (8.6x) compared to the European Biotechs industry average (7.9x).

Price to Sales Ratio vs Fair Ratio

What is GBY's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

GBY PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio8.6x
Fair PS Ratio11.1x

Price-To-Sales vs Fair Ratio: GBY is good value based on its Price-To-Sales Ratio (8.6x) compared to the estimated Fair Price-To-Sales Ratio (11.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst GBY forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€2.28
€5.49
+141.0%
63.0%€9.47€0.95n/a5
Nov ’25€1.62
€3.48
+114.3%
65.3%€7.32€0.92n/a5
Oct ’25€0.73
€3.48
+376.5%
65.3%€7.32€0.92n/a5
Sep ’25€0.71
€3.48
+389.1%
65.3%€7.32€0.92n/a5
Aug ’25€0.58
€3.51
+502.1%
65.3%€7.39€0.92n/a5
Jul ’25€0.31
€3.22
+937.5%
67.5%€7.36€0.92n/a6
Jun ’25n/a
€3.22
0%
67.5%€7.36€0.92n/a6
May ’25€0.44
€3.22
+633.8%
67.5%€7.36€0.92n/a6
Apr ’25€0.57
€3.22
+466.8%
67.5%€7.36€0.92n/a6
Mar ’25€1.00
€2.96
+197.4%
71.6%€7.48€0.94n/a6
Feb ’25n/a
€2.96
0%
71.6%€7.48€0.94n/a6
Jan ’25€0.50
€2.96
+488.6%
71.6%€7.48€0.94n/a6
Dec ’24€0.38
€2.96
+682.3%
71.6%€7.48€0.94n/a6
Nov ’24€0.55
€6.21
+1,031.3%
33.2%€9.44€3.40€1.628
Oct ’24€0.51
€5.51
+971.7%
43.3%€9.17€1.38€0.739
Sep ’24€0.83
€5.51
+562.4%
43.3%€9.17€1.38€0.719
Aug ’24€1.14
€6.80
+495.6%
54.7%€14.74€1.38€0.589
Jul ’24€1.09
€6.80
+523.1%
54.7%€14.74€1.38€0.319
Jun ’24€1.00
€6.80
+580.8%
54.7%€14.74€1.38n/a9
May ’24€1.42
€7.64
+437.9%
58.2%€14.58€1.37€0.449
Apr ’24€1.59
€10.39
+555.1%
39.2%€14.75€3.87€0.578
Mar ’24€2.72
€11.59
+326.5%
48.3%€23.45€3.94€1.009
Feb ’24€3.13
€12.00
+283.0%
56.0%€23.49€3.76n/a9
Jan ’24€2.85
€12.86
+351.7%
52.5%€23.52€3.76€0.509
Dec ’23€3.58
€13.63
+280.5%
52.5%€24.94€3.99€0.389
Nov ’23n/a
€14.77
0%
49.9%€25.77€5.15€0.559

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Teva Pharmaceutical Industries

US$19.0b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEV

US$15.85

7D

-1.6%

1Y

93.3%

Pharming Group

€485.0m

A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.

PHGN

€0.72

7D

-3.4%

1Y

-31.8%

Collegium Pharmaceutical

US$976.2m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

354

US$27.60

7D

-14.3%

1Y

20.0%